Smoke and Alcohol Free with EHealth and Rewards (SAFER) pregnancy study: a before-after study protocol by Breunis, L.J. et al.
PROTOCOL OPEN
Smoke and Alcohol Free with EHealth and Rewards (SAFER)
pregnancy study: a before−after study protocol
Leonieke J. Breunis 1, Marlou L. A. de Kroon1,2, Lyzette T. Laureij 1, Lieke de Jong-Potjer1, Eric A. P. Steegers1 and
Jasper V. Been 1,3,4✉
Despite existing interventions, tobacco smoking and alcohol consumption during pregnancy are common. The Smoke and Alcohol
Free with EHealth and Rewards (SAFER) pregnancy intervention combines monthly group sessions, access to a web-based platform
and incentives upon biochemically validated cessation for a maximum duration of 6 months to promote cessation of smoking and
alcohol use before and during pregnancy. To inform development of the SAFER pregnancy intervention, two focus groups with the
target population were held beforehand, with results reported here alongside the final SAFER pregnancy study protocol. In a before
−after study we aim to include 66 women who are pregnant or have a wish to become pregnant and who smoke and/or consume
alcohol (i.e. target population of the SAFER pregnancy intervention). The primary outcome measure is cessation of smoking and/or
alcohol use at 34−38 weeks of gestation, or after six group sessions if women did not become pregnant during the study period.
Secondary outcomes focus on the barriers and facilitators for implementation of the SAFER pregnancy intervention.
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INTRODUCTION
Smoking during the preconception period and/or pregnancy is
associated with many adverse health outcomes. It decreases
fertility and increases the risk of an ectopic pregnancy or
miscarriage1. In addition, smoking during pregnancy increases
the risk of adverse perinatal health outcomes, such as being small
for gestational age, preterm delivery, birth defects, and even
perinatal death2,3. Children born to mothers who smoke are also
more likely to develop asthma, obesity, and respiratory infections,
and are more likely to take up smoking later on4–6. Despite these
risks, only half of women who smoke, successfully quit smoking
because of their pregnancy or planning of pregnancy. As such, in
the European Region, 5.9% of pregnant women are daily
smokers7. In the Netherlands 3.5% of pregnant women smoke
throughout their entire pregnancy8. Risk factors for continuation
of smoking during pregnancy include having an unplanned
pregnancy, having a partner who smokes, and a low socio-
economic status (SES)9,10. Alcohol is another toxic substance that
is commonly used and its consumption is socially acceptable in
many cultures. Alcohol consumption during pregnancy is asso-
ciated with an increased risk of miscarriages, fetal growth
restriction, preterm delivery and Fetal Alcohol Spectrum Disorders
(FASD)11,12. FASD include a range of (developmental) disorders
and constitute a major cause of preventable intellectual disability
in children13. The prevalence of alcohol consumption during
pregnancy is estimated at 25% in Europe and 4.2% in the
Netherlands8,14; the global prevalence of FASD is estimated at
2.3%15. Risk factors for continuation of alcohol use during
pregnancy include a low educational level, a young maternal
age, frequent alcohol use before pregnancy and having a
depression16–18. Importantly, smoking and alcohol use during
pregnancy often co-occur resulting in cumulating health risks18,19.
Although a number of interventions successfully promote
smoking cessation during pregnancy, with relative risks for
smoking cessation ranging from 1.25 for less intensive interven-
tions to 1.44 for counselling, these are effective in only a minority
of pregnant women20,21. The evidence concerning promotion of
abstinence of alcohol during pregnancy is very limited22. This
indicates that there is a need to continue developing more
effective interventions tailored at pregnant women and women
with a wish to conceive who continue to smoke or use alcohol.
Combining various existing interventions or successful elements
of interventions can potentially optimise the effectiveness of
smoking cessation interventions20,21.
Recent studies indicate that provision of financial incentives (i.e.
rewards for a specific goal with the purpose to motivate) can be
effective for inducing behavioural change, including smoking
cessation23,24. Research on incentives for alcohol cessation is
scarce and has only been conducted among non-pregnant
participants, with variable results. One small study in non-
pregnant adolescents was unable to demonstrate a significant
impact of incentives on 36-week abstinence (odds ratio 1.21 [95%
CI 0.38–3.85])25. Two other studies in heavy drinking people
showed that incentives prolonged participation in the interven-
tion (84% versus 22% for 8-week intervention, p value < 0.001 (chi-
square test))26 and abstinence (69% versus 39% completed 8-
week intervention, p value < 0.05 (Breslow comparison) and 8.0
versus 2.9 consecutive days of abstinence, p value < 0.05 (multiple
regression analysis))26,27.
Attending group sessions to increase knowledge, social support
and health literacy, and eHealth-based interventions such as a
web-based platform, are also promising for reducing smoking
among women who are either pregnant or planning pregnancy,
with relative risks for smoking cessation ranging from 1.21 for
social support to 3.06 for eHealth-based interventions; however,
many women continue to smoke during pregnancy20,28. The
limited evidence concerning promotion of abstinence of alcohol
during pregnancy shows that health education is often part of
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successful interventions for behavioural change during pregnancy
and social support is important in helping women to reduce
alcohol use29,30. In addition, eHealth-based interventions concern-
ing alcohol cessation during pregnancy have been shown to be
effective in increasing alcohol abstinence during pregnancy (odds
ratio varying between 2.77 and 4.72) in favour of the eHealth-
based intervention31,32.
The effectiveness of a combination of incentives, group sessions
and an eHealth-based intervention to reduce smoking and alcohol
use has never been studied before, neither in pregnant nor in
non-pregnant women.
In the Smoke and Alcohol Free with EHealth and Rewards
(SAFER) pregnancy study, we will investigate whether the
combination of group sessions, a web-based platform and
provision of financial incentives upon validated cessation is
effective in reducing smoking and alcohol use in women before
and during pregnancy. Given the multiple novel aspects of the
intervention, the primary aim is to assess the feasibility and
acceptability of the SAFER pregnancy approach so as to
potentially inform design of a larger randomised experiment
ideally powered to assess changes in pregnancy outcomes. The
innovative multifaceted intervention has been developed in close
collaboration with the target population. In addition to presenting
the protocol for the SAFER pregnancy study, here we also report
results from the focus group study with members of the target
population that was undertaken prior to the SAFER pregnancy
study so as to inform the development of the SAFER pregnancy
intervention.
METHODS
The SAFER pregnancy study is an uncontrolled before−after study
embedded in primary care, designed to assess changes in smoking and
alcohol use among pregnant women and women with a wish to conceive
following a complex intervention consisting of group sessions, access to a
web-based platform, and provision of incentives upon validated smoking
and alcohol cessation. The SAFER pregnancy study has been registered in
the Netherlands Trial Register, reference NL7493 on 4 February 2019
(https://www.trialregister.nl/trial/7493). In preparation of the SAFER preg-
nancy study, we organised focus groups with the target population to
inform the development of the SAFER pregnancy intervention. We
discussed content of the group sessions, the nature and timing of the
incentives, and the potential ways of recruitment of participants. The
methods and results of this focus group study are described below,
followed by a more detailed description of the SAFER pregnancy
intervention.
Focus group study: setting and participants
Two focus groups with the planned target population of the SAFER
pregnancy study were held in February and April 2018. Potential
participants could be referred by healthcare providers (e.g. midwives,
gynaecologists and general practitioners) working in the municipality of
Zoetermeer, a city in the Netherlands, or register themselves following
recruitment via promotion material in local newspapers and social media if
they were interested in participation. Women were eligible if: (1) they were
planning pregnancy, were pregnant, or recently gave birth, (2) were over
18 years old, and (3) gave written permission for audiotaping of the focus
group. Women were excluded if they insufficiently understood the Dutch
language. The first focus group consisted of women who smoked at least
one cigarette a day or drank at least five units of alcohol per week during
pregnancy or while planning pregnancy. The second focus group
consisted of women who had successfully quit smoking or using alcohol
because of their pregnancy or planning of pregnancy. We intended to
include 8−12 women in each focus group.
Focus group study: data collection
Prior to the focus group study, participants received the statements that
were discussed during the focus group study (Supplementary Table 1) and
a questionnaire assessing personal characteristics by e-mail. The state-
ments were grouped into: knowledge, existing support, and future
support. Because extensive research on eHealth-based interventions for
addressing smoking and alcohol use in the target population already
existed, this topic was not discussed in the focus groups28,31–38. The
questionnaire addressed smoking and alcohol use by the participants and
their partners, whether they were already pregnant and whether they had
a Western or non-Western background. The focus group study was
conducted by three researchers (two at each focus group): L.J.B. guided the
focus groups; M.L.A.d.K. and L.T.L. took notes. The researchers did not
know the participants beforehand. The focus groups were conducted in
Zoetermeer and lasted a maximum of 2 h.
Each focus group started with an introduction explaining the aim of the
study and reassuring confidentiality. Both focus groups were audiotaped.
All participants received a gift voucher worth 25 euros.
Focus group study: data processing and analysis
All transcripts were transcribed verbatim, anonymised and returned to the
participants for member checking. Prior to analysis, L.J.B. developed a
coding scheme based on the framework of Fleuren et al., which states that
dissemination, adoption, implementation, and continuation are the four
consecutive stages within an innovation process39. According to this
framework, transition of one stage to the next may be affected by the end
user, the innovation itself, the socio-political environment, and by
characteristics of the organisation39. Therefore, each of these factors
should be taken into account when developing, implementing, and
evaluating interventions. We used this framework approach with thematic
content analysis to broaden our focus beyond evaluating aspects of the
innovation (the SAFER pregnancy intervention) solely. By taking this
approach we ensured that other aspects of the intervention that may
affect feasibility and acceptability were also taken into account40. Before
analysing the focus group interviews, subthemes were defined for each
factor (for example for the factor ‘end user’, transcripts could be coded as
emotions, knowledge, etc.). The factor ‘innovation’ consisted of multiple
components since the SAFER pregnancy intervention combines multiple
existing interventions. There was a different subheading within this factor
for each component of the intervention, except for eHealth as stated
before. During the analysis, some subthemes were added. The complete
coding scheme is shown in Supplementary Table 2. Transcripts were
independently coded by L.J.B. and L.T.L. If disagreement occurred, codes
were discussed with a third researcher (M.L.A.d.K.) until consensus was
reached. We used the qualitative software programme NVivo (QSR
International Ltd. Version 12) to support data analysis.
Focus group study: results
Participant recruitment proved challenging. Thirty-three women were
referred to the researchers; six women could not be reached despite
several phone calls and e-mails, and seven refrained from participation. Of
the remaining 20 women, 14 agreed to attend one of two focus group
interviews; the other women could not make it on the scheduled date and
time. Five of the 14 women however did not show up. Eventually, focus
group 1 consisted of five women: three were pregnant and two had a wish
to conceive. Focus group 2 consisted of four women: one had a wish to
conceive, one was pregnant and two recently gave birth. All nine women
participated because of their smoking behaviour; one woman had
experienced minor issues quitting alcohol use. Participant characteristics
are shown in Supplementary Table 3.
A summary of the lessons learned from the focus group study that we
implemented in the SAFER pregnancy intervention is shown in Table 1.
Detailed results and illustrative quotes are shown in Supplementary Table
4. In summary, participants regarded it is important to understand the
perspectives of women who smoke before and during pregnancy and
understand the difficulties they face when trying to quit smoking. A strong
motivation is important, but women report that this motivation decreases
when the smoking behaviour is addressed in a negative way or when
healthcare providers are perceived to ‘force’ cessation. Women who
successfully quit smoking indicated that it is best to make a plan on how to
quit: set a quit date, discuss potential use of nicotine replacement therapy
and plan how to deal with cravings and boredom. During cessation,
women stated that support in difficult moments should be easily
accessible, preferably 24/7. Women felt that during the group sessions
tips and tricks about smoking cessation should be shared, whereas
discussing information concerning a healthy lifestyle more generally was
undesirable. Incentives were not believed to increase motivation for
smoking cessation but were believed to support within the process of
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quitting. The type of incentives should be discussed beforehand and
women should have an option to choose which incentive they wish to
receive. Furthermore, most women preferred multiple smaller incentives at
brief intervals over larger ones at longer intervals. It was also felt stop-
smoking-interventions should be available at low or even no costs.
Due to the low number of participating women, data saturation might
not have been reached. Given the difficulty in recruiting women for the
focus groups and in the light of the relevant information collected to
inform the design of the SAFER pregnancy study, we pragmatically
decided to proceed with finalising the development of the intervention
and to start piloting it.
SAFER pregnancy study: study design
The SAFER pregnancy study is a prospective, uncontrolled before
−after study.
SAFER pregnancy study: setting and participants
The study will be conducted in Zoetermeer, Benthuizen (small village that
affiliated its care with Zoetermeer) and Rotterdam, the Netherlands. Previous
research indicated that the municipality of Zoetermeer (approximately
125,000 inhabitants and 1300 livebirths annually) had the highest perinatal
mortality in the Netherlands41, and it has a relatively large deprived
population with likely clustering of risk behaviours such as smoking and
alcohol use. Within Rotterdam (approximately 640,000 inhabitants and 7900
livebirths annually), more than half of children grow up in a neighbourhood
with low SES and one in five children grow up in poverty42.
Women are eligible if:
pregnant or having a wish to become pregnant within 6 months;
smoking at least one cigarette a day and/or drinking at least three units
of alcohol a week.
Exclusion criteria are:
less than 18 years of age;
more than 20 weeks pregnant;
insufficient mastery of the Dutch language;
unwilling to undergo urinary, and/or breath testing (when reporting
smoking), and/or blood testing (when reporting drinking alcohol).
urinary cotinine level below 50 µg/L, carbon monoxide (CO) level <7 parts
per million (ppm) (when reporting smoking) or PhosphatidylEthanol
(PEth) test below 7 µg/L (when reporting drinking alcohol) at inclusion;
use of hard drugs.
Eligible women will be informed about the study by their midwife,
obstetrician, primary care physician, healthcare provider of the outpatient
clinic ‘Achieving a Healthy Pregnancy’ of the Erasmus MC or other
healthcare providers (e.g. physiotherapist, physician at the centre for youth
and family). The Erasmus MC (University Hospital in Rotterdam) provides
an outpatient clinic (‘Achieving a Healthy Pregnancy’) for couples with a
wish to conceive. This outpatient clinic focuses on improving healthy
behaviour to promote a (healthy) pregnancy, and to prevent adverse
health outcomes for mother and child. Healthcare providers of Zoeterm-
eer, Benthuizen and the outpatient clinic are engaged in the study via
regular meetings, newsletters and regular personal contact with the study
team by phone and e-mail. If women are interested in participation, the
healthcare provider will send their contact information to the researcher. In
addition, participants will be recruited through promotion material (e.g.
posters at schools, in waiting rooms and centres for youth and family and
advertisement in local newspapers). Within 1 week, the researcher will
contact the potential participant via telephone and inform her about the
study and, if she is still interested in participating, make an appointment
for a home visit.
Information about the study and the informed consent form (ICF) are
sent by e-mail to the potential participant. During the home visit the study
will be further explained, the ICF will be signed, biochemical validations
(urinary cotinine level, CO breath test and/or PEth test to validate smoking
and/or alcohol use among potential participants) will be performed as
indicated, and a cessation plan will be made with the researcher (L.J.B.). A
quit date will be set within 2 weeks after the home visit, potentially difficult
moments will be discussed, and a plan to avoid or deal with these
moments will be devised by the participant. Using motivational
interviewing, motivation and self-confidence will be increased.
SAFER pregnancy study: intervention
Based on existing literature and the focus group study we developed the
SAFER pregnancy intervention, which consists of a web-based platform,
group sessions and provision of incentives upon validated cessation of
smoking and alcohol use in addition to care as usual. All components are
described in detail below.
Participants will actively be directed towards an existing web-based
platform: Smarter Pregnancy (www.slimmerzwangeronderzoek.nl). Smarter
Pregnancy has been demonstrated to improve nutrition and lifestyle
behaviour and is reimbursed by many Dutch health insurers33. For our
study, the platform will be made freely available and its use will be
encouraged. This platform maps the medical and non-medical (e.g. type of
food intake, substance abuse, physical activity) risk profile of participants
via online surveys. Based on this information it stimulates adoption of a
Table 1. Summary of the lessons of the focus group study that were implemented in the design (detailed results and illustrative quotes are shown in
Supplementary Table 4).
Part of SAFER pregnancy
intervention
Implementation in the SAFER pregnancy intervention
Home visit and quit plan Set a quit date, identify potential difficult moments, plan distraction and discuss the habit of smoking and
dealing with habits.
Discuss how to deal with relatives who smoke and do not smoke.
Discuss the option of using nicotine replacement therapy during pregnancy.
Group sessions Only focus on women who are pregnant or want to become pregnant.
Each session is a standalone session so women who already quit smoking share their experiences with women
who did not quit smoking yet.
Exchange tips and tricks and discuss nicotine replacement therapy.
Discuss hazards of smoking and alcohol consumption before and during pregnancy during an interactive and
informative session.
Focus group sessions on dealing with stress, distraction from smoking, identity, and diet.
Let the informative session be guided by an experienced lifestyle coach who knows different ways of cessation.
Online platform Actively refer participants to an online platform that provides help 24/7.
Incentives Let women choose which reward they prefer for cessation.
Provide monthly incentives instead of one large incentive over a longer period of time. Make the value of the
incentives larger over time to motivate quitting early during pregnancy and remaining abstinent over a longer
period of time.
Validation Only provide incentives after biochemical validation.
Costs Participation should be free.
Other Give information on cessation support for partners.
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healthy lifestyle using personalised e-mails. These contain tips, facts and
recommendations to promote healthy behaviour and healthy food recipes.
Participants will be allocated into groups (3−10 participants per group),
preferably based on the neighbourhood they live in. Participants will join
monthly group sessions with a maximum of six sessions. The group
sessions aim to provide peer support, increase self-efficacy, stimulate
avoiding risk behaviour, and adopt a healthy lifestyle by providing
information and organising activities concerning a healthy diet, sport
activities, and cessation of smoking and alcohol use. There is no particular
sequence of sessions; thus, women can enter the study at any time point.
Each session will take approximately 2 h. The first half hour of each
session will be used to introduce participants to each other and to share
experiences of the cessation process. The next 1.5 h will consist of other
activities as described below. A study team member will be present at each
group session.
Sport session: Two of the six sessions (with two other sessions between
them) will consist of yoga and power walking. The activities are
supervised by instructors with specific expertise in working with
pregnant women.
Informative session: One group session will be used to interactively
inform participants about the disadvantages of smoking and drinking
alcohol and the advantages of cessation. This will be discussed using
quizzes, and sharing of experiences and knowledge. This session will be
led by a lifestyle coach.
Identity session: Behaviour and someone’s identity are closely inter-
related; identity can influence behaviour43, but people may also base
their identity on their behaviours44. Smokers with a strong non-smoker
identity more often attempt to quit smoking, and transition from a
smoker identity towards a non-smoker identity may be necessary for
successful quitting45,46. Also, moral identity as a mother is an important
motivator for smoking cessation during pregnancy47, and transition to a
non-smoking mother identity seems important in relapse prevention48.
Drinking identity predicts problem drinking among college students49,50,
but the link between a strong drinking identity and alcohol cessation has
not been studied in relation to pregnancy. Whether strengthening the
good mother identity affects smoking and alcohol drinking cessation is
unknown. In this group session participants will explore their current and
future identities in relation to smoking, alcohol and becoming a mother.
Participants will be asked to search for images matching their ideas
concerning their current and future identities. In addition, they will be
asked to write a short text about their future self. The underlying idea is
that participants may elicit positive attributes when considering their
future non-smoking/non-drinking selves as opposed to them sustaining
their risk behaviours. This may be expected to provide internal
motivation to support cessation.
Adaptive content session: For this session participants may choose from
one of different subjects: a creative session (knitting or crocheting led by
an arts facility); a vocal session (voice liberation or singing workshop, led
by a singing teacher); mindfulness (led by a mindfulness trainer); or an
informative session about pregnancy and the postpartum period (led by
a midwife and maternity care organisation).
Cooking session: During this session, participants will prepare and enjoy
a healthy meal together. During the preparation participants will receive
information concerning healthy ingredients and the do’s and don’ts of
healthy cooking.
Participants are eligible to receiving incentives after biochemically
validated cessation of smoking and/or alcohol use. We used an existing
ethical framework when designing the various aspects of providing
incentives in this study51. During each group session, participants who
indicate that they quit smoking or drinking alcohol are invited to have this
Table 2. Value of the incentives participants of the SAFER pregnancy
study will receive per occasion when cessation of smoking and/or
alcohol use has been achieved.
Consecutive number of
times biochemically
verified cessationa
Value of the
incentive in euros if
smoking or alcohol
use are quit
Value of the
incentive in euros if
smoking and alcohol
use are quit
1 15 22.50
2 20 30
3 20 30
4 30 45
5 40 60
6 60 90
Total 185 277.50
aDuring each group session, participants who indicate that they quit
smoking or drinking alcohol are invited to have this biochemically
validated via a CO breath test (smoking) and/or PEth test (alcohol use).
As soon as cessation is validated, the participant will receive the incentive.
Wish to become pregnantDid not become pregnant during
period with sessions
S 1 S 2 S 3 S 4 S 5 S 6
Became pregnant during period
with sessions
Wish to become pregnant Pregnancy
Postpartum
period
S 1 S 2 S 3 S 4 S 5 S 6
Gave birth before the sixth session Pregnancy
Postpartum
period
S 1 S 2 S 3 S 4
Gave birth after the sixth session Pregnancy
Postpartum
period
S 1 S 2 S 3 S 4 S 5 S 6
End of study period Wish to become pregnant Pregnancy
Postpartum
period
S 1 S 2 S 3 S 4
End of project
*
*
*
*
*
Fig. 1 Main study endpoints in relation to a participant’s pregnancy status*. *Primary study endpoints are marked with an asterisk. S1−S6
= sessions 1−6.
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biochemically validated via a CO breath test (smoking) and/or PEth test
(alcohol use). As soon as cessation is validated, the participant will receive
the incentive. Incentives will be provided both at the individual and at the
group level. To decrease the costs of the intervention and to increase local
involvement, local entrepreneurs will be approached to provide incentives
in the form of, for example, vouchers to locally support the project.
Individual incentives are vouchers to be spent at local businesses such
as supermarkets, baby shops, or beauty salons. Tobacco products and
alcoholic beverages are excluded. The monetary value of each incentive is
listed in Table 2. The longer cessation is sustained, the more valuable the
reward will be. When a participant relapses, the value of the next incentive
will be reset. If a woman both smokes and uses alcohol, she is amendable
to receiving incentives for cessation in both areas. Cessation of either
smoking or drinking is followed by provision of ‘regular’ incentives,
cessation of both is followed by incentives representing a monetary value
of 1.5 times the ‘regular’ incentives (Table 2).
In addition to the individual incentives, group incentives will be
provided to support a local neighbourhood improvement project (e.g.
playground upgrade), which will be selected and developed by
participants during the group sessions. Allocating incentives at the group
level may be expected to promote feelings of shared responsibility and as
such may be an additional extrinsic motivator for cessation of risk
behaviour. The monetary value of the group incentives is comparable to
that of the individual incentives (Table 2).
SAFER pregnancy study: outcomes
The primary outcome is biochemically validated cessation of smoking or
alcohol use at (Fig. 1):
week 34−38 of gestation (if pregnant at inclusion or became pregnant
during participation); or
the end of the project period if <34 weeks pregnant at the time; or
the last validation after six group sessions in those who did not become
pregnant during participation.
The secondary outcomes are listed in Table 3. We will collect costs at the
individual level of running the programme including the web-based
platform and the group sessions to estimate costs per successful quitter.
Using estimates from existing meta-analyses on the primary adverse
outcomes associated with the risk behaviour that has been avoided by the
SAFER pregnancy approach, we will furthermore calculate crude estimates
of potential cost-effectiveness.
SAFER pregnancy study: data collection
Participants receive questionnaires through e-mail and fill them out online.
They receive a voucher worth 15 euros if they filled out the questionnaire.
Questionnaire items are listed in Table 4. Participants receive a
questionnaire at inclusion and 1 week before each group session. Women
who are pregnant during the study period also receive a questionnaire at
34−38 weeks gestation and a final questionnaire 1 week postpartum.
Women who do not become pregnant during the study period receive
their final questionnaire after the sixth group session. In addition, a log on
patient recruitment, collaboration with local entrepreneurs, and contact
with healthcare providers and participants will be kept by the research
team to explore barriers and facilitators for implementation of the
intervention. In the log quantitative data will be noted, such as the
number of potential participants referred and included and the amount of
incentives provided (outcome measures are shown in Table 3). In addition,
participants will fill out questionnaires about their experiences with the
intervention and study itself during their participation and at the end of
their participation. These data will give insight into acceptability and
feasibility of the SAFER pregnancy intervention and therefore potential
barriers and facilitators for proper implementation can be identified. These
potential barriers and facilitators will be further qualitatively evaluated in a
focus group study at the end of the SAFER pregnancy study, with the aim
to evaluate the acceptability and feasibility of the intervention, in three
separate focus groups with participants, leaders of the group sessions and
involved healthcare providers.
At inclusion, smoking will be confirmed with a hand-held CO monitor
(Micro+ smokerlyzer)52 and a urinary cotinine test53, and alcohol use via a
PEth54,55 test in 10mL of blood. The cut-off value to identify active (as
distinguished from passive) smoking in our study will be 7 ppm, in
accordance with the NICE guideline56. Urinary cotinine values above 50 µg/L
will be considered indicative of active (distinguished from passive)
Table 3. Secondary study parameters/endpoints.
Data group Data item Data source
Barriers and facilitators of implementation (process measures) How many sessions were attended by each participant Study log
How often participants logged in on the
web-based platform
Smarter Pregnancy
How many biochemical assessments were performed
and the results of each assessment
Study log and lab results
How many incentives were issued per person and
in total
Study log
How many local entrepreneurs were contacted and
how many agreed to provide incentives
Study log
Perceived efficiency and appreciation of the web-based
platform, the group sessions, and incentives
Experienced peer support and appreciation of the
platform, the group sessions, and the incentives
Questionnaires
Health behaviour before and during the study
and after delivery
Questionnaires
Reasons why lifestyle changes succeeded or failed Questionnaires
Evaluation of the group sessions Questionnaires
Costs The number of participants receiving incentives Study log
The amount of incentives received per participant Study log
The number of participants who achieve sustained
cessation
Study log
Pregnancy outcomes Date of delivery, singleton or multiple birth, birth
weight, gestational age, gender, place of birth
(e.g. hospital, home), type of delivery (e.g. caesarean
section), Apgar score, admission to the Neonatal
Intensive Care Unit (NICU), congenital abnormalities,
mortality
Letter for the general
practitioner if the
participant consents,
otherwise with a
questionnaire
Identity changes Identity factors associated with smoking status
and/or drinking status
Questionnaire
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smoking. Whole blood PEth values above 6 µg/L will be considered
indicative of alcohol use in the previous 2 weeks. If participants report
smoking cessation during the study period, this will be validated with the
CO test. At the primary endpoint, smoking cessation will be validated with
the CO test and the urinary cotinine test. Cessation of alcohol will be
validated with the PEth test.
SAFER pregnancy study: data analysis plan
The proportion of women who quit smoking or alcohol use at the primary
endpoint will be calculated as the number of women that have quit at this
endpoint divided by the total number of women included in the study.
Furthermore, we will use (backward) logistic regression analysis to explore
independent predictors of effectiveness of the intervention. Descriptive
statistics will be used for the secondary outcomes and results will be
reported in narrative and tabular form. Open questions within the
questionnaires will be evaluated qualitatively using thematic content
analysis.
SAFER pregnancy study: sample size calculation
Because vulnerable populations, as our target population, are difficult to
reach and recruit for participation in medical research57,58 and because we
aim to develop an intervention fit for the target population, we decided at
this stage to pragmatically perform an uncontrolled before−after study.
The overall aim is to obtain an estimate of potential effectiveness of the
SAFER pregnancy intervention, while assessing its feasibility and accept-
ability. As such, findings from this study are ideally placed to inform design
of a potential larger randomised experiment. The primary outcome is the
proportion of women attaining sustained cessation of alcohol use and/or
smoking. Because little research on interventions for alcohol cessation
during pregnancy exists and only a small number of women were referred
to the focus group study due to alcohol consumption, we based our
sample size calculation primarily on smoking cessation. In a recent
randomised controlled trial assessing the effectiveness of incentives to
promote smoking cessation during pregnancy, 22.5% of the women in the
intervention group reached the primary endpoint of cessation, versus 8.6%
in the control group59. Accordingly, we set our true proportion to 25% and
our null hypothesis proportion to 9%. With a power of 90% and a one-
sided alpha of 2.5%, our intervention group would have to contain 49
participants in order to assess effectiveness of the SAFER pregnancy
intervention versus the counterfactual scenario. Considering an expected
dropout of 25%, we aim to include 66 women, who smoke and/or
consume alcohol, at baseline.
SAFER pregnancy study: ethics and dissemination
The Medical Research Ethics Committee of the Erasmus MC approved the
study (NL67428.078.18). All participants will provide written informed
consent. Each participant will receive a study number and all identifiable
information of the participant and her baby will be stored separately from
other data collected during the study. Only the core researchers (L.J.B., M.L.
A.d.K. and J.V.B.) will have access to the identification list and the access
passwords for both datasets. Study documents and data will be stored for
15 years after completion of the study.
SAFER pregnancy study: safety
Due to the negligible risks of the SAFER pregnancy study, we will not
collect or report adverse events and a Data Safety Monitoring Board will
not be established. In concordance with the Guideline for Good Clinical
Practice, the study will be monitored at least once a year by an
independent and qualified monitor.60
DISCUSSION
Design of the SAFER pregnancy study was based on literature,
guidelines, and results of the focus group study described here
alongside the final protocol of the SAFER pregnancy study.
A major strength of the SAFER pregnancy intervention,
embedded in existing primary care networks, is that it has been
developed in close collaboration with the target population.
Strengths of the focus group study in itself were that we identified
barriers and facilitators for cessation by including women who
continued to smoke and women who quit smoking during
pregnancy in two different groups. In doing so, every participant
was able to speak freely without the risk of feeling judged.
Although we did not collect objective information regarding
socio-economic indicators from focus group participants, many of
them shared information during the discussions indicative of
having a low socio-economic status (e.g. poor financial status,
unemployment, single status, former drug abuse). Due to this, we
believe the participants of the focus group study were represen-
tative for the target population of the SAFER pregnancy study.
Limitations of the focus group study were the low number of
participants and the fact that alcohol use was low among included
women. Another strength of the SAFER pregnancy intervention is
that it combines several interventions previously shown to be
effective in promoting cessation of smoking and/or alcohol use.
Also, the intervention addresses different aspects of addiction (e.g.
identity, stress) and besides providing preliminary data on
potential effectiveness this study we will assess facilitators and
barriers to implementation of the intervention. Together the
findings of the study may thus inform the design of a larger
randomised trial to assess the impact of the SAFER pregnancy
intervention on cessation and birth outcomes. Limitations of our
study are that we will not have a control group and that, due to a
lack of financial resources, we are unable to actively engage
partners in the intervention.
The innovative SAFER pregnancy approach can potentially bring
about substantial health benefits for mothers and children by
addressing two important and common risk factors for adverse
pregnancy outcomes which are entirely preventable.
Table 4. Data collection with questionnaires.
Data group Data item
Baseline characteristics Age
Parity
Ethnicity
Household income and financial problems
Educational level
Marital status and relational problems
Due date
Lifestyle behaviour (smoking, alcohol use,
diet, activity, drugs)
Statements concerning lifestyle changes
according to the Attitude—Social
influence—Self-efficacy (ASE)-model
Statements concerning identity
Level of addiction Age started smoking
Number of cigarettes smoked per day
Smoking partner
Intention and motivation to quit
Obstetric characteristics Use of birth control
Number of living children
Number of miscarriages/stillbirths
Number of premature births
Number of children born small for
gestational age
Number of children born with congenital
abnormalities
Number of deceased children
Identity Different statements concerning smoking,
alcohol use and motherhood
LJ Breunis et al.
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Reporting summary
Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
DATA AVAILABILITY
We intend to provide an anonymised version of the dataset upon reasonable request.
CODE AVAILABILITY
Results of this study including the statistical code will be published in a peer-
reviewed journal and be presented at (inter)national meetings.
Received: 7 February 2020; Accepted: 23 September 2020;
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